After becoming one of the fastest-growing memecoins to reach a $1 billion market cap, $BRETT eyes growing enthusiasm and expansion in Asia SEOUL, KOREA, July 16, 2024 (GLOBE NEWSWIRE) — Popular memecoin $BRETT today announced that it… Read More »$BRETT Is Now Listed on Leading South Korean Exchange Bithumb
Tribblytics Empowers Tribble’s AI Agent, Bringing Unprecedented Efficiency to Enterprises LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) — Tribble, an AI-native company out to automate the entire Request for Proposal (RFP) process, has launched Tribblytics.… Read More »Tribble Releases Tribblytics, the Latest AI Agent Innovation for RFPs, And Achieves Significant Milestone of 125,000 Agent Interactions on the Platform
OAKLAND, Calif., July 17, 2024 /PRNewswire/ — Today, Turnitin, a leading provider of technology solutions in academic integrity, announced its AI paraphrasing detection feature. Integrated within Turnitin’s AI writing capabilities, the feature helps educators and… Read More »Turnitin Helps Educators and Publishers Advance Critical Thinking with New AI Paraphrasing Detection Feature
HONG KONG, July 16, 2024 /PRNewswire/ — Hong Kong’s Bar Leone debuts at No.1 in Asia’s 50 Best Bars 2024, sponsored by Perrier, at a live awards ceremony in Hong Kong. Bar Leone ranks… Read More »BAR LEONE IN HONG KONG NAMED THE BEST BAR IN ASIA, SPONSORED BY PERRIER, AS THE ASIA’S 50 BEST BARS 2024 LIST IS REVEALED
Insurance carriers, health plans and financial services companies that offer employee benefits to employer groups stand to benefit from the automation of post-sales communication and document processing personalized to each new employer group SANTA CLARA,… Read More »Ushur Launches Prebuilt Onboarding Automation Solution for Group and Worksite Benefits Companies
FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1 marker.Trial expands from patients afflicted with Recurrent Grade… Read More »NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation